Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 ...
Chemical structure of PSMA-617. 68 Ga and 177 Lu can bind to PSMA-617 ...
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved ...
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant ...
Chemical structures of 177 Lu-PSMA-617 and 177 Lu-PSMA I&T. | Download ...
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive ...
Full article: Metastatic Castration-Resistant Prostate Cancer: Insights ...
FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration ...
The synthetic scheme of PSMA-617 and drug of 175/177 Lu-PSMA-617 [8 ...
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium ...
Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 ...
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model ...
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617 ...
Lutetium 177 Psma Therapy
Characterization of Non-Specific Uptake and Retention Mechanisms of ...
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of ...
Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy ...
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617 ...
ASCO 2025: Lutetium-177-PSMA-617 in Oligo-Metastatic Hormone Sensitive ...
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA ...
Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model ...
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate ...
(PDF) Review of 177Lu-PSMA-617 in Patients With Metastatic Castration ...
Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 ...
Intermittent Radioligand Therapy with 177Lu-PSMA-617 for ...
Fast, quantitative SPECT/CT acquisition following multiple therapy ...
Lutetium 177 PSMA Treatment | Koru International Medical Center
Lutetium-177-PSMA-617 Effective for Advanced Prostate Cancer
A 177Lu-labeled albumin-binder-conjugated PSMA-617 derivative with ...
(PDF) Safety of Lutetium-177 prostate-specific membrane antigen-617 ...
Mediso - Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo ...
靶向放射性配体疗法177Lu-PSMA-617治疗前列腺获FDA授予优先审评资格-上市-医保-临床适应症-香港济民药业
ESMO 2025: Discussant – Phase III Trial of [177Lu]Lu-PSMA-617 Combined ...
PSMA-617 | CAS:1702967-37-0 | Xi'an Confluore Biological Technology Co ...
Biodistribution data of 44 Sc-PSMA-617 and 177 Lu-PSMA-617 ...
Lutetium-177 PSMA-617 Delays Progression in Early-Stage Prostate Cancer ...
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in ...
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration ...
Validation of Prognostic and Predictive Models for Therapeutic Response ...
Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with ...
Internalization of 44 Sc-, 68 Ga-and 177 Lu-labeled PSMA-617 in LNCaP ...
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ...
Theranostic Perspective for PSMA-positive prostate cancerpptx | PPTX
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in ...
Outcomes for Patients with Metastatic Castration-Resistant Prostate ...
Schematic model of [177 Lu]Lu-PSMA-617 internalization in endogenous ...
The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in ...
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
177 Lu-PSMA-617 radioligand therapy for a patient with lymph node ...
Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the ...
177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with ...
Analysis of PSMA expression and outcome in patients with advanced ...
Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 ...
177 Lu-PSMA-617 radioligand therapy for biohemically recurrent prostate ...
ASCO 2025: Plasma Epigenomic Profiling to Reveal Molecular Correlates ...
(PDF) 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with ...
Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved ...
Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 ...
177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant ...
A Review of Theranostics: Perspectives on Emerging Approaches and ...
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic ...
Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with ...
Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in ...
HPLC profile of the 177 Lu-PSMA-617 therapeutic doses (7.4 GBq ...
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After ...
Frontiers | Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA ...
FDA approves expanded label for 177Lu-PSMA-617 in mCRPC | Urology Times
(PDF) PSMA-617 inhibits proliferation of human prostate cancer cells ...
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic ...
(PDF) VISION trial: 177 Lu-PSMA-617 for progressive metastatic ...
Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men ...
Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy: A New Frontier in ...
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in ...
(PDF) [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved ...
Human ABC and SLC Transporters: The Culprit Responsible for Unspecific ...
Frontiers | 177Lu-labeled PSMA targeting therapeutic with optimized ...
SUO 2025: PSMAndARPI: Phase II Study of 177Lu-PSMA-617 Plus Androgen ...
RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers ...
EU：177Lu-PSMA-617 放射配体治疗高负荷转移性激素敏感性前列腺癌的新方案-MedSci.cn
[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC ...
Molecular imaging and biochemical response assessment after a single ...
00237-3/asset/791cc06c-708e-4448-9fa7-941f17df1063/main.assets/gr2_lrg.jpg)
